Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics (NASDAQ: ACRS) will release full Phase 1a results for its anti-TSLP/IL-4R bispecific antibody ATI-052 and announce lead indication selection for its ITK/JAK3 inhibitor ATI-2138 before markets open on April 28, 2026.

Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) will release full Phase 1a results for its anti-TSLP/IL-4R bispecific antibody ATI-052 and announce lead indication selection for its ITK/JAK3 inhibitor ATI-2138 before markets open on April 28, 2026.

The company will host a webcast and conference call with slides on April 28, 2026 at 8:30 AM EST; the live and archived webcast will be available on the company Events page and archived for 30 days.

Argus Apr 28 session

-4.31% close to close Open Argus

Details

News Market Reaction – ACRS

In the Apr 28 session, ACRS declined 4.31%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights upcoming, potentially detailed clinical information for both ATI-052 an...

Analysis

This announcement highlights upcoming, potentially detailed clinical information for both ATI-052 and ATI-2138, building on a pipeline that already includes a completed Phase 2 enrollment of 109 patients for bosakitug and encouraging Phase 2a ATI-2138 data. With cash of $151.4M and narrowed 2025 net loss of $64.9M, the company has some financial flexibility. Investors may watch for durability of efficacy, safety signals, and how new results influence future development priorities and potential financing needs.

Key Figures

Cash & securities: $151.4M Net loss 2025: $64.9M ATM proceeds: $39.8M +5 more

Cash & securities

$151.4M

Balance as of Dec 31, 2025 (10-K)

Net loss 2025

$64.9M

Full-year 2025 net loss vs $132.1M in 2024 (10-K/8-K)

ATM proceeds

$39.8M

Aggregate gross proceeds from 12.7M shares sold Mar 2–9, 2026 (8-K)

Additional ATM sale

$20.0M

Aggregate gross proceeds from 5.7M shares sold Mar 10, 2026 (8-K)

Shares sold Mar 2–9

12.7M shares

Common stock sold under sales agreement (8-K)

Shares sold Mar 10

5.7M shares

Common stock sold under sales agreement (8-K)

Market cap

$600,553,824

Pre-update market value at $4.41 per share

Short interest

5.18%

Short float percentage from risk context

Historical Context

5 past events · Latest: Apr 08

5 events

1. Apr 08

   Conference participation

   24h Move

   +5.3%

   Announced participation in H.C. Wainwright inflammatory skin disease virtual conference.

2. Mar 27

   Clinical data update

   24h Move

   +0.0%

   Presented Phase 2a ATI-2138 ePoster with substantial week-12 efficacy improvements.

3. Mar 20

   Clinical presentation

   24h Move

   -1.3%

   Announced upcoming ePoster on Phase 2a ATI-2138 results at AAD 2026.

4. Mar 18

   Trial enrollment complete

   24h Move

   -5.7%

   Completed enrollment of 109 patients in Phase 2 bosakitug trial for atopic dermatitis.

5. Mar 03

   Conference participation

   24h Move

   -0.3%

   Planned fireside chat at Leerink Partners 2026 Global Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1a, multiple ascending dose, bispecific antibody, itk/jak3 inhibitor

4 terms

phase 1a medical

"full results from its Phase 1a single and multiple ascending dose trial"

Phase 1a is the initial part of a human clinical trial where a new drug or therapy is given to a small group of people for the first time to check safety, how the body handles it, and to identify appropriate dosing. Investors watch phase 1a like a vehicle's first test drive: clear safety and predictable behavior reduce risk and unlock value by allowing larger, more expensive trials to proceed and by increasing the chance of regulatory progress.

multiple ascending dose medical

"Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R"

A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.

bispecific antibody medical

"its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

itk/jak3 inhibitor medical

"results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138"

An itk/jak3 inhibitor is a drug that blocks two immune-system proteins, ITK and JAK3, which act like on/off switches for immune-cell signaling; by dampening those signals the medicine reduces overactive immune responses and inflammation. Investors pay attention because therapies that target both switches can treat autoimmune diseases, inflammatory conditions, or some cancers, so study results, side-effect profiles and regulatory outcomes can greatly affect a drug developer’s commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial markets tomorrow, April 28, 2026.

Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss these updates. The live and archived webcast will be available on the Events page of the Company’s website: https://investor.aclaristx.com/events. The webcast will be archived on the same page for 30 days following the event. If you would rather access the call via telephone: To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations related to the timing of the announcement related to the ATI-052 Phase 1a SAD/MAD results and the results of its lead indication selection process for ATI-2138. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, risks associated with interim, topline and preliminary data, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2025, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris and on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Aclaris (ACRS) announce on April 28, 2026 about ATI-052?

They will publish complete Phase 1a single and multiple ascending dose trial results for ATI-052. According to the company, the release includes full safety and tolerability data and trial findings published before market open on April 28, 2026.

When and how can investors access the Aclaris (ACRS) April 28, 2026 webcast?

The webcast and conference call will begin on April 28, 2026 at 8:30 AM EST. According to the company, the live and archived webcast will be on the company Events page and archived there for 30 days.

What will Aclaris (ACRS) disclose about ATI-2138 on April 28, 2026?

Aclaris will announce its lead indication selection for ATI-2138, the ITK/JAK3 inhibitor. According to the company, the announcement will state which indication was selected and the rationale from the internal selection process.

Will the Aclaris (ACRS) webcast include slides and a Q&A on April 28, 2026?

Yes, the company will host a webcast and conference call with slides and access details. According to the company, registered participants receive dial-in information and a unique PIN to join the live call and Q&A.

How long will Aclaris (ACRS) keep the April 28, 2026 webcast available online?

The webcast will be archived for 30 days following the event on the company Events page. According to the company, both the live and archived webcast will remain accessible via the Events page during that 30-day period.